Blog
Valuable TargetsAdvanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
SWIM-816 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
SWIM-816 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
SWIM-816: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
OCU410ST Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
OCU410ST Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
OCU410ST: Phase 2/3. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
Read →
JC242 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
JC242 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
JC242: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
EXV-801 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
EXV-801 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
EXV-801: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
RTx-015 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
RTx-015 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
RTx-015: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Umbilical Cord-Derived Mesenchymal Stem Cells(Ankara City Hospital Bilkent) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Umbilical Cord-Derived Mesenchymal Stem Cells(Ankara City Hospital Bilkent) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Umbilical Cord-Derived Mesenchymal Stem Cells(Ankara City Hospital Bilkent): Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers.
Read →
AZD-5156 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
AZD-5156 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
AZD-5156: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
SG404 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
SG404 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
SG404: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Faecal microbiota transplantation(University of Aarhus) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Faecal microbiota transplantation(University of Aarhus) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Faecal microbiota transplantation(University of Aarhus): Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
Read →
TUM-012 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
TUM-012 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
TUM-012: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
LMN-201 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
LMN-201 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
LMN-201: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
MAD-0004J08 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
MAD-0004J08 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
MAD-0004J08: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →